Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects
Open Access
- 3 May 2004
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 33 (12) , 1191-1199
- https://doi.org/10.1038/sj.bmt.1704461
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemiaBone Marrow Transplantation, 1999
- Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhoodThe Lancet, 1997
- Allogeneic blood stem cell transplantation in advanced hematologic cancersBone Marrow Transplantation, 1997
- Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histologyThe American Journal of Medicine, 1996
- Formulation and stability of busulfan for intravenous administration in high-dose chemotherapyCancer Chemotherapy and Pharmacology, 1996
- Toxicities of total-body irradiation for pediatric bone marrow transplantationInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Bone Marrow Transplantation for Pediatric LeukemiaPediatric Annals, 1991
- Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantationCancer Chemotherapy and Pharmacology, 1989
- Pharmacokinetic and metabolic studies of high-dose busulphan in adultsEuropean Journal of Clinical Pharmacology, 1989
- Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and CyclophosphamideNew England Journal of Medicine, 1983